125 related articles for article (PubMed ID: 37198512)
1. Myositis developing after Covid-19 mRNA vaccine: Case Report.
Tosunoğlu B; Güneş HN; Çokal BG; Yoldaş TK
Acta Neurol Taiwan; 2023 Jun; 32(2)():79-81. PubMed ID: 37198512
[TBL] [Abstract][Full Text] [Related]
2. Adverse events of a third dose of BNT162b2 mRNA COVID-19 vaccine among Korean healthcare workers.
Lee DY; Kang DY; Kim E; Lee SJ; Baek JH; Lee JS; Park MY; Im JH
Medicine (Baltimore); 2023 Mar; 102(11):e33236. PubMed ID: 36930126
[TBL] [Abstract][Full Text] [Related]
3. Safety of COVID-19 vaccines.
Al Khames Aga QA; Alkhaffaf WH; Hatem TH; Nassir KF; Batineh Y; Dahham AT; Shaban D; Al Khames Aga LA; Agha MYR; Traqchi M
J Med Virol; 2021 Dec; 93(12):6588-6594. PubMed ID: 34270094
[TBL] [Abstract][Full Text] [Related]
4. A retrospective evaluation of side-effects associated with the booster dose of Pfizer-BioNTech/BNT162b2 COVID-19 vaccine among females in Eastern Province, Saudi Arabia.
Hassan YAM; Daud Ali M; Al-Eid RR; Al-Ghuraya FA; Essa Alqasimi Z; Ahmad A; Eltrafi Z; Ghosn SA
Vaccine; 2022 Nov; 40(49):7087-7096. PubMed ID: 36404426
[TBL] [Abstract][Full Text] [Related]
5. Inflammatory myopathy following coronavirus disease 2019 vaccination: A systematic review.
Ding Y; Ge Y
Front Public Health; 2022; 10():1007637. PubMed ID: 36339243
[TBL] [Abstract][Full Text] [Related]
6. Post-COVID-19 vaccination inflammatory syndrome: A case report.
Durucan I; Guner S; Kilickiran Avci B; Unverengil G; Melikoglu M; Ugurlu S
Mod Rheumatol Case Rep; 2023 Jan; 7(1):280-282. PubMed ID: 35556127
[TBL] [Abstract][Full Text] [Related]
7. Progression of hemolysis in a patient with hereditary spherocytosis after the second dose of COVID-19 mRNA vaccine.
Nomura J; Seki M; Abe S; Kobayashi T; Okitsu Y; Fukuhara N; Takahashi S; Harigae H; Kameoka J
Hum Vaccin Immunother; 2023 Dec; 19(1):2165381. PubMed ID: 36625832
[TBL] [Abstract][Full Text] [Related]
8. Orbital myositis and scleritis after anti-SARS-CoV-2 mRNA vaccines: A report of three cases.
Savino G; Gambini G; Scorcia G; Comi N; Fossataro C; Stanislao Rizzo
Eur J Ophthalmol; 2023 Sep; 33(5):NP29-NP34. PubMed ID: 36062603
[TBL] [Abstract][Full Text] [Related]
9. Side effects of Pfizer/BioNTech (BNT162b2) COVID-19 vaccine reported by the Birzeit University community.
Abukhalil AD; Shatat SS; Abushehadeh RR; Al-Shami N; Naseef HA; Rabba A
BMC Infect Dis; 2023 Jan; 23(1):5. PubMed ID: 36604613
[TBL] [Abstract][Full Text] [Related]
10. Safety and tolerability of the novel 2019 coronavirus disease (COVID-19) vaccines among people with epilepsy (PwE): A cross-sectional study.
Massoud F; Ahmad SF; Hassan AM; Alexander KJ; Al-Hashel J; Arabi M
Seizure; 2021 Nov; 92():2-9. PubMed ID: 34391030
[TBL] [Abstract][Full Text] [Related]
11. Evaluate the side effect associated with COVID-19 vaccine on adolescents in Riyadh, Saudi Arabia: A cross-section study.
Aldali JA; Alotaibi FT; Alasiri GA; Almesned RA; Alromih AM; Almohandes AM; Alsenidi SF
Saudi Med J; 2022 Nov; 43(11):1248-1253. PubMed ID: 36379531
[TBL] [Abstract][Full Text] [Related]
12. Myocarditis, Pulmonary Hemorrhage, and Extensive Myositis with Rhabdomyolysis 12 Days After First Dose of Pfizer-BioNTech BNT162b2 mRNA COVID-19 Vaccine: A Case Report.
Al-Rasbi S; Al-Maqbali JS; Al-Farsi R; Al Shukaili MA; Al-Riyami MH; Al Falahi Z; Al Farhan H; Al Alawi AM
Am J Case Rep; 2022 Feb; 23():e934399. PubMed ID: 35173141
[TBL] [Abstract][Full Text] [Related]
13. Correlation of Immunogenicity and Reactogenicity of BNT162b2 and CoronaVac SARS-CoV-2 Vaccines.
Zhang R; Leung KY; Liu D; Fan Y; Lu L; Chan PC; To KK; Chen H; Yuen KY; Chan KH; Hung IF
mSphere; 2022 Apr; 7(2):e0091521. PubMed ID: 35285250
[TBL] [Abstract][Full Text] [Related]
14. Correlation of adverse effects and antibody responses following homologous and heterologous COVID19 prime-boost vaccinations.
Cheng A; Hsieh MJ; Chang SY; Ieong SM; Cheng CY; Sheng WH; Chang SC
J Formos Med Assoc; 2023 May; 122(5):384-392. PubMed ID: 36564299
[TBL] [Abstract][Full Text] [Related]
15. Adverse reactions to the BNT162b2 and mRNA-1273 mRNA COVID-19 vaccines in Japan.
Kitagawa H; Kaiki Y; Sugiyama A; Nagashima S; Kurisu A; Nomura T; Omori K; Akita T; Shigemoto N; Tanaka J; Ohge H
J Infect Chemother; 2022 Apr; 28(4):576-581. PubMed ID: 35058126
[TBL] [Abstract][Full Text] [Related]
16. Early experience of COVID-19 vaccine-related adverse events among adolescents and young adults with rheumatic diseases: A single-center study.
Haslak F; Gunalp A; Cebi MN; Yildiz M; Adrovic A; Sahin S; Barut K; Kasapcopur O
Int J Rheum Dis; 2022 Mar; 25(3):353-363. PubMed ID: 34978376
[TBL] [Abstract][Full Text] [Related]
17. Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial.
Munro APS; Feng S; Janani L; Cornelius V; Aley PK; Babbage G; Baxter D; Bula M; Cathie K; Chatterjee K; Dodd K; Enever Y; Qureshi E; Goodman AL; Green CA; Harndahl L; Haughney J; Hicks A; van der Klaauw AA; Kanji N; Libri V; Llewelyn MJ; McGregor AC; Maallah M; Minassian AM; Moore P; Mughal M; Mujadidi YF; Holliday K; Osanlou O; Osanlou R; Owens DR; Pacurar M; Palfreeman A; Pan D; Rampling T; Regan K; Saich S; Bawa T; Saralaya D; Sharma S; Sheridan R; Thomson EC; Todd S; Twelves C; Read RC; Charlton S; Hallis B; Ramsay M; Andrews N; Lambe T; Nguyen-Van-Tam JS; Snape MD; Liu X; Faust SN;
Lancet Infect Dis; 2022 Aug; 22(8):1131-1141. PubMed ID: 35550261
[TBL] [Abstract][Full Text] [Related]
18. Tolerability of COVID-19 Infection and Messenger RNA Vaccination Among Patients With a History of Kawasaki Disease.
Beckley M; Olson AK; Portman MA
JAMA Netw Open; 2022 Aug; 5(8):e2226236. PubMed ID: 35960521
[TBL] [Abstract][Full Text] [Related]
19. COVID-19 vaccination in people with multiple sclerosis, real-life experience.
Alroughani R; Al-Hashel J; Abokalawa F; AlMojel M; Farouk Ahmed S
Clin Neurol Neurosurg; 2022 Sep; 220():107374. PubMed ID: 35961255
[TBL] [Abstract][Full Text] [Related]
20. Reactions following Pfizer-BioNTech COVID-19 mRNA vaccination and related healthcare encounters among 7,077 children aged 5-11 years within an integrated healthcare system.
Malden DE; Gee J; Glenn S; Li Z; Mercado C; Ogun OA; Kim S; Lewin BJ; Ackerson BK; Jazwa A; Weintraub ES; McNeil MM; Tartof SY
Vaccine; 2023 Jan; 41(2):315-322. PubMed ID: 36351861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
